Do you want to read an article? Please log in or register.
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL
Lymphoma
Related content
ASH 2025
Lymphoma
TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up
EHA 2026
Leukemia
CLL14: Final 9-year analysis confirms long-term efficacy of one-year fixed-duration venetoclax plus obinutuzumab in previously untreated CLL
Breast Cancer
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Lancet Oncol
Brunt AM, Cafferty FH, Kirby AM, Patel J, Sydenham MA, Haviland JS, Griffin S, Chivardi C, Fleming H, Coles CE, Bloomfield DJ, Chan C, Cleator S, Goodman A, Griffin CL, Kirwan CC, Nabi Z, Sawyer E, Somaiah N, Syndikus I, Venables K, Wheatley DA, Yarnold JR, Bliss JM
doi: 10.1016/S1470-2045(26)00076-8
CHICAGO 2026
Genitourinary Cancer
EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma
Lymphoma
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL
Blood
Abramson JS, Siddiqi T, Gordon LI, Lunning MA, Wang M, Arnason JE, Kamdar M, Maloney DG, Shadman M, Andreadis CB, Sehgal A, Solomon SR, Ghosh N, Hidalgo-López JE, Wang J, Ding X, Ogasawara K, Singh A, Palomba ML
doi: 10.1182/blood.2025032270
Lymphoma
The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group
Eur J Cancer
Ostrowska B, Domanska-Czyz K, Giza A, Taszner M, Tomaszewska A, Targonski L, Dabrowska-Iwanicka A, Poplawska L, Konecki R, Kotarska M, Szymanski M, Borawska A, Swierkowska M, Druzd-Sitek A, Paszkiewicz-Kozik E, Mroz-Zycinska E, Zimowska-Curyło D, Owczarek-Kaczmarek J, Drozd-Sokolowska J, Tajer J, Osiadacz W, Rymkiewicz G, Michalski W, Basak G, Krzanowski J, Sacha T, Zaucha JM, Walewski J, Romejko-Jarosinska J
doi: 10.1016/j.ejca.2026.116789
ELCC 2026
Lung, Respiratory and Thoracic Cancer
PALOMA-2: Durable clinical outcomes and manageable safety with SC amivantamab plus lazertinib in patients with EGFR-mutated NSCLC
RECOMMENDED
Breast Cancer
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang XA, Cao S, Bidard FC
doi: 10.1016/j.annonc.2025.11.018
ESMO 2025
Genitourinary Cancer